The role of human papillomavirus (HPV) proteins in the pathogenesis ofcervical intra-epithelial neoplasia (CIN) and invasive cervical cancer is poorly understood. To characterize E4 protein expression in 49 paraffin-embedded cervical biopsies representing different histopathologic grades of disease, antibodies were elicited to a synthetic peptide corresponding to amino acids 20-34 of a protein predicted to be encoded by the HPV 16 E4 open reading frame. The E4 protein was detected throughout the spectrum of CIN, from CIN 1 to CIN 3. Expression was localized to the cell nucleus, primarily in the superficial layers of the squamous cervical epithelium. Ultrastructural studies showed that the E4 protein was organized into compact, intranuclear arrays 25-35 nm in diameter. E4 protein expression was also demonstrated in some histologically normal tissues containing HPV 16 DNA, but not in any of five cervical cancers containing HPV 16 DNA. These results suggest that E4 pro-
Introduction
The relationship between human papillomavirus (HPV)' infection and disease of the human uterine cervix, ranging from cervical intra-epithelial neoplasia (CIN) to squamous cell carcinoma (SCC) is now well established (1) (2) (3) . Several studies have suggested that CIN may progress from low grade disease (CIN 1) to high grade disease (CIN 3) over a period of months to years, and that CIN 3 is associated with a high risk of progres-sion to invasive cervical cancer (4, 5) . HPV types 6 and 11 have been detected primarily in association with low grade cervical disease (condyloma acuminatum and CIN 1), whereas types 16, 18, 31, 33, and 35 have been detected in association with high grade cervical disease and a higher risk of progression to malignancy (6-1 1) . Of the latter group, HPV 16 has been the most frequently detected HPV type in several studies of women with CIN or cervical cancer (12) .
The genome of HPV 16 consists ofthe early region (E) and the late region (L) (13) . The latter can encode the LI and L2 proteins which are thought to be the major and minor capsid proteins, respectively; these are believed to be expressed only in productive viral infection (14) . The E region proteins El and E2 are important in viral transcriptional regulation (15) (16) (17) , whereas the E6 and E7 proteins are thought to be more directly involved in malignant transformation, with the latter playing the major role (18) (19) (20) . In contrast, the function ofthe proteins encoded by the E4 open reading frame (ORF) is unknown. In plantar warts containing HPV la DNA, the E4 proteins appear to constitute a family ofpolypeptides ranging in size from 10 to 17 kD. They are of considerable interest because they are expressed in great abundance, comprising up to one-third of the total cellular mass (21) . Similarly, mRNA species encoded by the E4 ORF are among the most abundant viral transcripts in biopsies of CIN and condyloma (22, 23) .
At 4 .2M guanidium isothiocyanate (Sigma Chemical Co., St. Louis, MO), 0.5M 2-ME (Sigma Chemical Co.), and 0.5% (wt/vol) N-lauroylsarcosine (Sigma Chemical Co.), and stored at -20 C. A biopsy of a region fulfilling colposcopic criteria (24) for cervical disease was obtained during the same visit from each subject. Cervical biopsies were fixed in formalin, embedded in paraffin, and cut into 4-,um tissue sections; these sections were prepared for routine histopathologic examination and for immunohistochemical studies using the antibodies specific for the E4 protein described below. Histopathology was evaluated using standard diagnostic criteria for the female genital tract (24) . Preparation of the HPV 16 and HPV 6 E4 synthetic peptides. A peptide corresponding to amino acids 20-34 (Gly-Ser-Thr-Trp-ProThr-Thr-Pro-Pro-Arg-Pro-Ile-Pro-Lys-Pro) of the E4 ORF of HPV 16 (HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ) was synthesized by solid-phase techniques using commercially available amino acids and tert-butoxy carbonyl-protecting groups (Peninsula Laboratories, Belmont, CA) (25) . A peptide sequence found in both HPV 6 and 11, corresponding to amino acids 33-46 (Asn-Leu-Leu-His-Thr-Pro-Pro-His-Arg-Pro-Pro-Pro-Leu-Cys) of the E4 ORF of HPV 6 was also synthesized. As indicated in Fig. 1 , both sequences are derived from the homologous regions of their respective E4 ORFs. After synthesis, the amino acid compositions and sequences of the peptides were confirmed by amino acid analysis and automated Edman degradation, respectively. For the purpose of covalent coupling of the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide to thyroglobulin, a cysteine residue was added to the peptide's carboxyl terminus during synthesis; conjugation of the peptide to thyroglobulin was then performed using the heterobifunctional cross-linker m-maleimidobenzoyl-n-hydroxysuccinimide ester (MBS) (Pierce Chemical Co., Rockford, IL) (26) .
A synthetic peptide corresponding to the entire predicted HPV 16 E4 ORF was synthesized as well. The HPV 16 E4 ORF does not encode an NH2-terminal methionine, and the predicted sequence ofthe native protein includes a splice from the El ORF to amino acid 10 ofthe E4 ORF (27) . This sequence was therefore prepared synthetically using a peptide synthesizer (No. 9050; Milligen, Inc., Cambridge, MA) and N-a-fluorenylmethoxylcarbonyl (Fmoc)-protected amino acids activated as pentafluorophenyl esters (28) . Protected amino acids and resins (substituted at 0.9 mEq/g) used for synthesis were purchased from Milligen, Inc. Synthesis was accomplished using successive cycles of deprotection with 20% wt/vol piperidine and coupling in the presence of l-hydroxybenzotriazole (Aldridge Chemical Co., Milwaukee, WI) as described (28) . Peptides were cleaved from 2 g of resin by acidolysis using 30 ml ofa solution containing 95% trifluoroacetic acid (Aldridge Chemical Co.), 5% distilled water, and 1 mg ofphenol for a period of 8 h. The solution was separated from the resin, evaporated, and extracted with 200 ml of cold ether. The precipitated peptide was dried, resuspended in 100 ml of 5% acetic acid, lyophilized, and characterized by amino acid analysis and NH2-terminal sequencing.
Preparation of affinity-purified HPV 16 E4 peptide-specific antisera. To elicit antibodies to synthetic peptide HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , the peptide-thyroglobulin conjugate was emulsified with CFA and injected into New Zealand White rabbits; 6 wk later, the conjugate was administered with IFA, and the animals were bled 10 d thereafter. The IgG fraction was precipitated from the corresponding pre-immune sera and from the hyperimmune E4 antisera with 2 M ammonium sulfate, followed by anion-exchange chromatography with DEAE-cellulose (Sigma Chemical Co.). For the purpose of affinity purification, the synthetic peptide was conjugated to BSA with the heterobifunctional cross-linker succinimidyl 4-(n-maleimidomethyl) cyclohexane-l-carboxylate (SMCC) (Pierce Chemical Co.), and the peptide-BSA conjugate linked to an Affigel 15 column (Bio-Rad Laboratories, Richmond, CA). Bound (E4 peptide-specific) IgG was eluted in 20 mM glycine buffer, pH 2.5, and neutralized with 30 mM Tris HC1 buffer, pH 8.0. The E4 peptide-specific IgG, the pre-immune IgG, and the IgG fraction of the same immune sera that did not bind the column were assessed for reactivity to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , at an initial concentration of 1.4 ug/ml, were then added in serial 1:2 dilutions in blocking buffer containing 0.17% BRIJ 35 (Pierce Chemical Co.), beginning with a dilution ofthe initial antibody preparation of 1:50. Each dilution was tested in duplicate. The plates were incubated at 37°C for 3 h and the wells were then washed with BRIJblocking buffer. 5 X 104 cpm of '25I-protein A were added in BRIJblocking buffer to each well and the plate was incubated for 3 h at 37°C. Finally, the wells were washed with BRLJ-blocking buffer, cut out of the plate, and the bound radioactivity was quantitated by gamma counting. The results for each dilution are given as the average of the duplicate wells.
In a separate experiment, polystyrene microtiter wells were incubated overnight with 5 Mg/ml ofHPV16 E4 (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] for the full-length protein described above was studied by RIA (as described above), and by Western blot analysis. 2 synthetic full-length E4 protein were subjected to SDS-PAGE using 18% polyacrylamide in the resolving gel (29) , and the protein was transferred to a nitrocellulose membrane (30) . The membrane was incubated in 10 ng/ml of affinity-purified antibodies to HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] for 1.5 h at 370C, followed by incubation in 15,000 cpm/ml of '25I-protein A for 1.5 h at room temperature. The membrane was washed and exposed to Kodak XAR 5 film overnight at -700C. Immunohistochemistry. Formalin-fixed, paraffin-embedded cervical biopsies were cut into sections 4 um in thickness, placed on glass slides coated with aminopropyltriethoxysilane (AES) (Sigma Chemical Co.), and baked overnight at 60'C. Each tissue was assessed with preimmune IgG and affinity-purified IgG at a concentration of 1.4 Mg/ml. Tissues were also assessed with immune IgG from which the peptidespecific antibodies had been removed by affinity chromatography; these antibodies, which did not bind the peptide, were also used at a concentration of 1.4 Mg/ml. Immunohistochemistry was performed according to the method of Hsu and Raine (31) . Slides were deparaffinized in xylene, followed by graded ethanol washes from 100% ethanol to 70% ethanol. Slides were washed in 0.2% Tween (Sigma Chemical Co.) in PBS, followed by two washes in PBS. 10% normal goat serum in PBS was added to the slides for 30 min at room temperature in a humidity chamber. The slides were incubated with the IgG preparations described above in PBS with 0.05% Tween for 16 h at 4VC or for I h at room temperature, and were washed in PBS with 0.2% Tween. Biotinylated goat anti-rabbit IgG in PBS with 0.05% Tween was added for 30 min (ABC; Vector Laboratories, Inc., Burlingame,'CA). Avidinalkaline phosphatase conjugate in PBS with 0.05% Tween was added to the slides for 1 h at room temperature, followed by incubation with Red alkaline phosphatase substrate (Vector Laboratories, Inc.) for 1 h at room temperature in the dark. The slides were washed in distilled water, counterstained lightly with hematoxylin, dehydrated through graded washes from 70% to 100% ethanol, and mounted with Permount.
To be considered positive for the E4 protein, each tissue was required to satisfy the following criteria for antibody specificity: (a) affinity-purified antibodies to E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] -bound epithelial, but not stromal structures; (b) the IgG fraction of the pre-immune sera did not bind epithelial structures when used in the same concentration as the affinity-purified antibodies; and (c) immune IgG from which the E4-specific antibodies had been removed by affinity chromatography did not bind epithelial structures when used in the same concentration as the affinity-purified antibodies. The latter criterion was used in place ofcompetitive inhibition experiments with the soluble synthetic peptide because the peptide precipitated onto the surface of the slide during this assay.
Immunoelectronmicroscopy. Immunoelectron microscopy was performed on a biopsy of a cervical lesion obtained at the time of cervical conization using previously described techniques (32, 33) . Subsequent histopathologic assessment of tissue adjacent to the area of the biopsy demonstrated CIN 2. The biopsy specimen was immediately fixed in 4% paraformaldehyde in double-distilled water at 40C for 2 h. The specimen was cut into blocks measuring 1 mm X I mm X t mm, (where t equals the thickness ofthe epithelium), infiltrated successively in 4% paraformaldehyde with 10, 20, 40, and 78% sucrose in PBS, pH 7.2, and shock-frozen in slush nitrogen (-2100C). Ultrathin frozen sections were obtained on dry glass knives in an Ultracut FC-4E unit at -120'C (Reichert AG, Vienna, Austria). Sections were collected with droplets of 4% paraformaldehyde in 2.3 M sucrose in PBS and placed after thawing onto carbon-reinforced Pioloform F hexagonal gold grids (Wacker Chemie, Munich, FRG). Nonspecific binding sites were blocked with 0.1% gelatin and 0.5% BSA in PBS, and subsequently with goat nonimmune serum. The sections were then incubated for 1 h in 700 ng/ml antibodies to HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] in PBS containing 0.1% gelatin. Sections were then incubated with affinity-purified goat antirabbit IgG conjugated with 5-nm colloidal gold particles (Janssen, Beerse, Belgium). As a control, sections were also incubated in equal concentrations of rabbit pre-immune IgG. After staining with uranyl acetate, the specimens were stabilized with 1.0% methylcellulose (Methocyl; Fluka Feinchemikalien, Neu-Ulm, FRG), and examined at 80 kV with a Jeol JEM-1200 EX electron microscope.
Detection ofHPV DNA. The HPV type present in the cervix was determined by Southern blot hybridization of cervical swab material obtained before cervical biopsy. The guanidium isothiocyanate collection medium containing exfoliated cervical cells was extracted with phenol/chloroform, followed by isopropanol precipitation to partially purify the DNA. DNA was digested with 10 U Pst I for 2 h at 370C in 20 gl, and the fragments were electrophoresed in a 1% agarose gel. Southern blot hybridization (34) was performed with probes consisting of 32P-labeled nick-translated genomic DNA ofHPV types 16, 18, and 31 separately, and a mixture of probes corresponding to HPV 6 and-11. Initial washes were performed under conditions of temperature midpoint -250C. After appropriate exposure to Kodak XAR-5 film at -70'C, the blots were rewashed under conditions oftemperature midpoint -10C and re-exposed.
Polymerase chain reaction studies for the detection of HPV DNA were performed on 10 histologically normal tissue blocks using a modification of the method of Shibata et al. (35) Southern blot analysis. Membranes were exposed to Kodak XAR-5 film at -70'C; clearly detectable signal was usually seen within 1-2 h of exposure.
Positive controls for the presence of tissue and the integrity of the reaction consisted of the amplification of human alpha hemoglobin DNA from each tissue. As a positive control for HPV DNA amplification, cloned DNA corresponding to each ofthe HPV types was amplified as well. Three types ofnegative controls were used: (a) to minimize the possibility of false-positives due to contamination from one specimen to another in the laboratory, each mixture with all components of the reaction except the target DNA was amplified; (b) reaction mixtures containing the cloned HPV DNA of each type were amplified with each primer set to rule out cross-reactivity, and (c) histologically normal cervical tissues from women whose cervical swabs were HPVnegative, and whose tissues were negative for the E4 protein by immunohistochemistry, were studied to minimize the possibility ofcontamination due to tissue processing and/or nonspecificity of the amplification signal.
HPV [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide were obtained from hyperimmune sera by affinity purification and characterized using a solid-phase RIA. As a measure of the specificity of these antibodies, their reactivity to the immunizing peptide was compared with a peptide corresponding to the same region ofthe HPV 6 and 11 E4 ORF (Fig. 2 a) . The affinity-purified IgG exhibited reactivity for the HPV 16 immunizing peptide in concentrations as low as 280 pg/ml, representing a dilution of the initial antibody preparation of 1:5,000.
In contrast, these antibodies did not recognize the HPV 6 and 11 E4 peptide, indicating that they were specific for the HPV 16 E4 sequence. In addition, a control antibody preparation consisting of an equal concentration of IgG antibodies prepared from the pre-immune serum did not exhibit any reactivity to the HPV 16 E4 peptide. Similarly, IgG from the non-peptide binding fraction of the immune serum did not exhibit reactivity (data not shown), providing further evidence for the specificity of the affinity-purified antibodies.
To determine ifthe antibodies to HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] could recognize the full-length HPV 16 E4 protein, a 98 amino acid polypeptide corresponding to the entire predicted E I-E4 spliced gene product was synthesized as described above. Antibodies to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide bound the full-length polypeptide when tested either by Western blotting (data not shown) or solid-phase RIA (Fig. 2 b) , indicating that the epitope specified by amino acids 20-34 ofthe HPV 16 E4 ORF is antigenic within the context ofthe predicted full-length E4 protein. However, the reactivity of the antibodies to HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] was approximately four times greater for the small immunizing peptide than for the full-length protein. In the experiment depicted in Fig. 2b , the affinity-purified IgG reacted with the small immunizing peptide at concentrations as low as 550 pg/ml, representing a dilution ofthe initial antibody preparation of 1:3,000. In contrast, these antibodies reacted with the full-length E4 protein at concentrations as low as 2.4 ng/ml, which corresponded to a dilution ofabout 1:700.
Expression ofthe E4 protein in CINand cervical carcinoma tissues. Immunohistochemical studies of 49 cervical tissues with antibodies to HPV 16 E4 120-34] were performed in order to answer the following questions: Is the E4 protein expressed in HPV1 6-infected, histologically abnormal tissues? Ifso, what is the location of the E4 protein within the cell? How does expression vary with the stage ofcervical disease? In which cell layers of the squamous epithelium is the E4 protein expressed and is its expression linked to cellular differentiation? The results of these studies are presented in Table I and Fig. 3 .
12 tissues with histologic abnormalities ranging from CIN 1 to CIN 3 were obtained from subjects whose corresponding cervical swabs contained HPV 16 DNA (Table I) ofthe E4 protein was found in all grades ofCIN; it was detected primarily in the middle and superficial cell layers, and in many, but not all cells comprising these layers (Fig. 3 A) . In all grades of CIN, the E4 protein was detected only in the epithelial cell nucleus. When high and low grade CIN were present in the same tissue, E4 protein expression was generally more marked in areas containing the latter. However, expression did not correlate with cell differentiation per se, since the E4 protein was detected in lesions containing CIN 3, which exhibit little or no squamous differentiation. Instead, the location of the E4 protein within a lesion appeared to correlate with the location of HPV DNA as determined by in situ hybridization (Fig. 3, B and C).
In addition to lesions containing CIN, five invasive cancer tissues were obtained from subjects whose corresponding cervical swabs contained HPV 16 DNA. In these biopsies, the presence of HPV DNA was confirmed by in situ hybridization. However, in contrast to expression of the E4 protein in the superficial layers of CIN, the E4 protein was not detected in any ofthe cervical carcinoma tissues, even though these tissues contained HPV DNA. This finding was investigated further using the CaSki cell line, which contains HPV 16 DNA and was derived from a cervical cancer (31, 32) . The E4 protein was not detected in this cell line with the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] antibodies by immunohistology (data not shown).
To determine the location ofthe E4 protein within the nuclei of HPV-infected cells, immunoelectron microscopy was performed on ultrathin cryosections of a cervical lesion using the E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] antibodies. Approximately 120 cells per section from the superficial cell layers of the epithelium of a cervical lesion were screened. Arrays ofspherical structures 25 to 35 nm in diameter were observed in the nuclei of 10 cells. These structures appeared to resemble partially assembled or partially degraded virions (Fig. 4, A and B) . The more compact arrays were labeled with gold particles, localizing the E4 protein to these structures (Fig. 4 B) . No (39, 40) . However, it is not known if any proteins specified by the viral genome are expressed in these tissues. This question was addressed by examining histologically normal tissues adjacent to the lesions described above. Of the 12 CIN tissues containing HPV 16 DNA, adjacent histologically normal tissue was present in 6. In three ofthese six tissues, E4 protein expression was noted in areas that were otherwise normal histologically (Fig. 3 D) , even though in situ hybridization studies ofthe same tissues revealed HPV DNA only in the lesional areas. This finding led to the examination of two tissues that were entirely normal histologically from patients whose cervical swabs contained HPV 16 DNA. E4 protein expression was noted in one of these two tissues. Although HPV 16 DNA could not be detected in this tissue by in situ hybridization, it was readily detected in a paraffin section of the same tissue using the polymerase chain reaction. In contrast, although hemoglobin DNA was successfillly amplified from each of the samples, no HPV DNA was detected in three histologically normal, E4 protein-negative tissues from patients whose cervical swabs did not contain HPV DNA. Similarly, controls consisting of amplification of all components of the reaction except HPV DNA were negative for HPV amplification, and among the positive HPV DNA controls, there was no crossreactivity between primers and probes for each HPV type. Specificity ofantibodies to the HPV 16 E4 protein in cervical tissues. The results described above indicate that in cervical epithelia containing HPV 16 DNA, the E4 protein is expressed in some histologically normal tissues and in all grades of CIN, but not in cervical cancer. To investigate the possibility that the E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] antibodies were actually recognizing a normal non- DNA. The tissue was examined by immunohistochemistry for the presence of the E4 protein using 1.4 jig/ml of the affinity-purified IgG antibodies to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide. Nuclei containing the E4 protein stain red (arrows) and are localized to the middle and superficial cell layers of the epithelium. Studies were also conducted with the same tissue using IgG obtained from the pre-immune serum and the non-peptide binding fraction of the immune serum; these antibodies did not bind the tissue (data not shown). (Table I ). An additional six tissues were obtained from subjects whose corresponding cervical swabs contained HPV 6/1 1 DNA, and none ofthese tissues were bound by the HPV 16 E4 antibodies. Consistent with their specificity for the HPV 16 E4 peptide demonstrated by RIA, this finding indicates that these antibodies react with tissues from subjects infected with HPV 16 DNA, but do not react with tissues from HPV-negative subjects or subjects infected with HPV 6 or 11 DNA, regardless of lesional status.
Discussion
Genital HPV infections are rapidly increasing in incidence (41) among both men and women, and the incidence of high grade CIN is increasing as well (42) . In the United States, over 14,000 new cases of invasive SCC of the cervix are reported annually, resulting in -7,000 deaths per year (43) . In many developing countries, cancer of the cervix is a leading cause of death among young women (44) . Thus, the prevalence of HPV as a sexually transmitted pathogen and its established connection to cancer underlie the need for a bet-ter understanding of HPV protein expression and the role of HPV proteins in the pathogenesis of cervical disease. RNA in situ hybridization studies ofHPV-infected cervical tissues have shown that transcripts from most of the early region ORFs can be detected in cervical biopsies (22) . Of the early region transcripts, mRNA transcribed from the E4 ORF appears to be the most abundant in CIN tissues containing HPV 16 DNA. Similarly, mRNA from the E4 ORF was found to be the most abundant viral transcript in cervical condyloma acuminatum containing HPV 6 DNA (23) . While the foregoing studies have documented the presence of HPV mRNAs in genital tissues, little is known about the corresponding proteins in these sites. Thus, in the present study, we have used E4 protein-specific antibodies to determine the presence and location ofthe E4 protein in HPV-infected cervical tissues, and the relationship between E4 protein expression and the severity of the associated histopathologic abnormalities.
Immunohistochemical studies with the affinity-purified antibodies to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide indicated that they reacted with the HPV 16 sequence, but not with the corresponding sequence of HPV 6 or 1 1; this kind ofHPV type-specificity was sought in this study in order to use this immunologic reagent to discriminate between HPV 16 and HPV 6-or 11-infected cells. We further sought to determine ifthe antibodies that had been elicited to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide could bind the corresponding region ofthe full-length HPV 16 E4 protein. As indicated in Fig. 2 (Fig. 3) . Previous studies have shown that E4 mRNA in CIN containing HPV 16 DNA is also found in the same epithelial cell strata (22) . Similarly, late region protein expression occurs in the upper cell layers of the epithelium (14) . One interpretation of these findings is that HPV gene expression is linked to cell differentiation, since the middle and superficial layers of the epithelium contain cells that are more differentiated than cells comprising the basal layer. However, DNA in situ hybridization studies ofboth high and low grade lesions (e.g., Fig. 3 C) show that most ofthe cells harboring substantial quantities of HPV DNA are also located in the middle and superficial cell layers, indicating that these strata contain the highest DNA copy number. Thus, a second interpretation of the localization data is that expression of the E4 protein in the superficial layers of these tissues may simply be due to an increased viral DNA copy number in the cells comprising these layers. This in turn may be associated with a higher level of E4 mRNA and protein expression in these cells. This explanation is supported by the observation that E4 protein expression is also evident in the middle and superficial cell layers ofCIN 3 lesions harboring HPV 16 DNA (Fig. 3 A) (46) . Additional studies will be required to determine whether loss of E4 protein expression is causally related to the oncogenic process or is simply an associated finding.
In addition to its expression in CIN lesions, E4 protein expression can be detected in some histologically normal tissues containing HPV 16 DNA, whether these tissues are adjacent to lesional areas or are completely normal histologically (Table I) . This finding was unexpected, since HPV DNA and mRNA have rarely been found in such tissues by in situ hybridization. However, by analyzing a larger number of cells using the Southern blot hybridization technique, HPV DNA could be detected in histologically normal tissue located up to 5 cm from lesions shown to contain HPV DNA (39, 40 Our immunohistochemical and immunoelectron microscopy studies localize E4 protein expression to the cell nuclei of HPV-infected tissues. In contrast, Doorbar et al. detected large quantities of E4 protein in the cytoplasm of plantar warts infected by HPV la; they also found that the E4 ORF ofthis HPV type can encode a family ofpolypeptides differing in size, posttranslational modifications, and possibly, functions (21) . Breitburd et al. detected the E4 protein in both cytoplasmic and nuclear inclusions ofHPV 1-infected warts, and observed that cell keratinization was disturbed in cells containing the E4 protein (49) . However, HPV la, in contrast to HPV 16, is not believed to be a sexually transmitted pathogen and causes only benign lesions ofthe skin. Thus, localization ofthe HPV 16 E4 protein exclusively to the cell nucleus using the antibodies described in this report may be due to intrinsic differences in the biology of these two HPV types. Alternatively, other HPV 16 E4 protein variants could be present in the cytoplasm and these might lack the epitope recognized by antibodies to the HPV 16 E4 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] peptide. Evidence for this includes the observation ofE4 protein expression in the cytoplasm ofa small number of CIN biopsies positive for HPV 16 or 18 DNA using antibodies to a segment of the E4 protein expressed in Escherichia coli (50) . It is also possible that the concentration ofthe E4 protein in the cytoplasm of these cells is too low to be detected by our assay.
The significance of E4 protein expression for the pathobiology of CIN and invasive cancer is not yet known. Studies with bovine papillomavirus indicate that mutation of its E4 ORF does not alter the transforming ability ofthe virus (51) . Because viral capsid proteins are present in the cell nucleus, the nuclear location of the E4 protein may be consistent with a role in the process of virus maturation or as a structural protein. If so, it would be functionally analogous to a "late region" protein as suggested by Doorbar et al. (21) . Our ultrastructural studies are consistent with this hypothesis; within the nucleus, the E4 protein appears to be organized into regular arrays that have the appearance of viral particles, but with a diameter less than that of an intact viral capsid, which is 55 nm (52). Of note, however, Li and L2 gene expression are not necessarily linked to E4 expression, because in contrast to our finding that E4 expression often occurs in high grade CIN, most cases of high grade CIN are not found to contain the LI and L2 proteins (14) . Further studies will be needed, however, to determine the significance ofthese findings for the function ofthe E4 protein, the significance of its loss of expression in cervical cancer, and the prognostic implications of the detection of the protein in normal tissues.
